24(R),25-Dihydroxycholesterol | 60103-14-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 24(R),25-Dihydroxycholesterol
• 英文别名: (24R)-3β,24,25-Trihydroxy-cholest-5-ene；(3R,6R)-6-[(3S,8S,9S,10R,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methylheptane-2,3-diol
• CAS: 60103-14-2
• 化学式: C₂₇H₄₆O₃
• 分子量: 418.66
• InChiKey: OFNJCHBCBBSWHW-PJXSLZQESA-N

物化性质

• 沸点：
  554.4±25.0 °C(Predicted)
• 密度：
  1.08±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  60.7
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  24(R),25-Dihydroxycholesterol 在 吡啶 、 potassium carbonate 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Stereocontrolled syntheses of 24(S),25-epoxycholesterol and related oxysterols for studies on the activation of LXR receptors

  摘要：

  Efficient syntheses are described of desmosterol (4), the corresponding 24(S),25 epoxide (6) and various analogs of 6 for evaluation as ligands and functional activators of LXR receptors. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(98)02181-9
• 作为产物：
  描述：

  3β,24-dihydroxycholesta-5,25-diene 3-(tetrahydropyran-2-yl) ether 在 盐酸 、 叔丁基过氧化氢 、 lithium aluminium tetrahydride 、 重铬酸吡啶 、 bis(acetylacetonate)oxovanadium 、 乙醇 、 (R)-1,1'-Bi-2-naphthol 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 苯 为溶剂， 反应 29.5h， 生成 24(R),25-Dihydroxycholesterol
  参考文献：
  名称：

  Koizumi, Naoyuki; Ishiguro, Masaji; Yasuda, Mitsuhiro, Journal of the Chemical Society. Perkin transactions I, 1983, # 7, p. 1401 - 1410

  摘要：

  DOI：

文献信息

• Meiosis regulating compounds
  申请人：——

  公开号：US20010005757A1

  公开（公告）日：2001-06-28

  Certain compounds, structurally related to natural compounds which can be extracted i.a. from bull testes and from human follicular fluid, can be used for regulating the meiosis in oocytes and in male germ cells. Some of these compounds are useful in the treatment of infertility, whereas other compounds are useful as contraceptives. These compounds have the structural formula 1 wherein the substituents are as defined in the specification.

  某些化合物在结构上与可以从公牛睾丸和人类卵泡液中提取的天然化合物相关，可用于调节卵母细胞和男性生殖细胞中的减数分裂。其中一些化合物对治疗不孕症有用，而其他化合物则可用作避孕药。这些化合物具有结构式，其中取代基如规范中定义。
• Process for the preparation of (24R)-24,25-dihydroxysteroid compounds
  申请人：KUREHA KAGAKU KOGYO KABUSHIKI KAISHA

  公开号：EP0776905A2

  公开（公告）日：1997-06-04

  A process for producing a (24R)-24,25-dihydroxysteroid compound which comprises carrying out a catalytic asymmetric dihydroxylation reaction on a steroid compound having a carbon-carbon double bond in the side chain in the presence of an osmium complex having a hydroquinidine derivative using a heterogeneous solvent system prepared by adding at least one organic solvent selected from tetrahydrofuran, acetonitrile, acetone, 1,4-dioxane, N,N-dimethylformamide and N,N-dimethylacetamide to a tert-butanol/water two-component solvent system.

  一种生产(24R)-24,25-二羟基类固醇化合物的工艺，包括在具有氢醌烷衍生物的锇络合物存在下，在侧链中具有碳-碳双键的类固醇化合物上进行催化不对称二羟基化反应，该反应使用的异质溶剂系统是通过添加至少一种选自四氢呋喃的有机溶剂来制备的、将至少一种选自四氢呋喃、乙腈、丙酮、1,4-二氧六环、N,N-二甲基甲酰胺和 N,N-二甲基乙酰胺的有机溶剂加入叔丁醇/水双组 分溶剂体系。
• Treatment for age-related macular degeneration (AMD)
  申请人：——

  公开号：US20030162758A1

  公开（公告）日：2003-08-28

  The present invention addresses the treatment of age-related macular degeneration using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, reverse cholesterol transport components, such as transporters and HDL fractions, are utilized as diagnostic and therapeutic targets for age-related macular degeneration. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or Bruch's membrane is reduced.

  本发明利用与动脉粥样硬化类似的致病机制的调节来治疗老年性黄斑变性。在更具体的实施方案中，反向胆固醇转运成分，如转运体和高密度脂蛋白组分，被用作老年性黄斑变性的诊断和治疗靶标。在一个具体的实施方案中，视网膜色素上皮和/或布鲁氏膜的脂质含量降低。
• Treatments for age-related macular degeneration (AMD)
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US20030229062A1

  公开（公告）日：2003-12-11

  The present invention addresses the treatment of age-related macular degeneration using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, reverse cholesterol transport components, such as transporters and HDL fractions, are utilized as diagnostic and therapeutic targets for age-related macular degeneration. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or Bruch's membrane is reduced.

  本发明利用与动脉粥样硬化类似的致病机制的调节来治疗老年性黄斑变性。在更具体的实施方案中，反向胆固醇转运成分，如转运体和高密度脂蛋白组分，被用作老年性黄斑变性的诊断和治疗靶标。在一个具体的实施方案中，视网膜色素上皮和/或布鲁氏膜的脂质含量降低。
• Compositions and methods for modulating HDL cholesterol and triglyceride levels
  申请人：——

  公开号：US20040137423A1

  公开（公告）日：2004-07-15

  The invention provides methods for identifying agents that modulate HDL-levels in animals by evaluating the ability of LXR-modulating agents to increase ABCA1-gene expression in a cell as well as using such agents to treat conditions involving lower than normal HDL-levels, higher than normal triglyceride levels and the like.

  本发明提供了通过评估 LXR 调节药剂增加细胞中 ABCA1 基因表达的能力，以及使用此类药剂治疗高密度脂蛋白水平低于正常、甘油三酯水平高于正常等病症，从而确定调节动物体内高密度脂蛋白水平的药剂的方法。